TG Therapeutics (NASDAQ:TGTX) vs. Affymax (OTCMKTS:AFFY) Financial Analysis

Affymax (OTCMKTS:AFFY) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Affymax and TG Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affymax	0	0	0	0	0.00
TG Therapeutics	0	1	5	0	2.83

TG Therapeutics has a consensus price target of $40.67, suggesting a potential upside of 26.45%. Given TG Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Affymax.

Profitability

This table compares Affymax and TG Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Affymax	N/A	N/A	N/A
TG Therapeutics	-5.42%	-8.32%	-3.40%

Volatility & Risk

Affymax has a beta of 6.39, suggesting that its stock price is 539% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.

Institutional & Insider Ownership

58.6% of TG Therapeutics shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Affymax and TG Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affymax	N/A	N/A	N/A	N/A	N/A
TG Therapeutics	$264.79 million	18.91	$12.67 million	($0.10)	-321.60

TG Therapeutics has higher revenue and earnings than Affymax.

Summary

TG Therapeutics beats Affymax on 6 of the 10 factors compared between the two stocks.

About Affymax

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.